Sphingolipid targets in cancer therapy
نویسندگان
چکیده
منابع مشابه
Sphingolipid targets in cancer therapy.
Considerable progress has been made recently in our understanding of the role of ceramide in the induction of apoptotic cell death. Ceramide is produced by cancer cells in response to exposure to radiation and most chemotherapeutics and is an intracellular second messenger that activates enzymes, leading to apoptosis. Because of its central role in apoptosis, pharmacologic manipulation of intra...
متن کاملApoptotic Sphingolipid Ceramide in Cancer Therapy
Apoptosis, also called programmed cell death, is physiologically and pathologically involved in cellular homeostasis. Escape of apoptotic signaling is a critical strategy commonly used for cancer tumorigenesis. Ceramide, a derivative of sphingolipid breakdown products, acts as second messenger for multiple extracellular stimuli including growth factors, chemical agents, and environmental stress...
متن کاملSphingolipid and Ceramide Homeostasis: Potential Therapeutic Targets
Sphingolipids are ubiquitous in eukaryotic cells where they have been attributed a plethora of functions from the formation of structural domains to polarized cellular trafficking and signal transduction. Recent research has identified and characterised many of the key enzymes involved in sphingolipid metabolism and this has led to a heightened interest in the possibility of targeting these pro...
متن کاملLung Cancer: Targets and Therapy
s excluded as irrelevant (n = 1320) Full text paper obtained for further review (n = 164) 99 studies further excluded: • • • • • • • No astragalus involved in TCM treatment (n = 54) Not all subjects received astragalus-based TCM (n = 8) No platinum included in the chemotherapy or chemotherapy combined with radiotherapy (n = 10) No usable endpoints were included (n = 16) Not a controlled trial (...
متن کاملNew Targets for Therapy in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is the fourth cause of cancer-related death in the US, accounting for an estimated 37.000 in 2010 (Jemal et al., 2010). Only about 10-15% of newly diagnosed PDAC are potentially resectable, while the majority of patients present with locally advanced or metastatic cancer. The median survival of non operable patients treated with standard chemotherapy rang...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Cancer Therapeutics
سال: 2006
ISSN: 1535-7163,1538-8514
DOI: 10.1158/1535-7163.mct-05-0420